29 septiembre 2014
Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/MLP3hoJudVU/140929090346.htm
